Personalized medicine in screening for malignant disease: A review of methods and applications

Biomarker Insights

Volumn 8, Issue , 2013, Pages 9-14

  Schmalfuss, F ^a   Kolominsky Rabas, P L ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Breast cancer; Colorectal cancer; Early detection; Lung cancer; Personalized medicine; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; MICRORNA;

BREAST CANCER; BREATH ANALYSIS; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; EARLY DIAGNOSIS; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; PERSONALIZED MEDICINE; PROSTATE CANCER; REVIEW; RISK ASSESSMENT;

EID: 84874196886     PISSN: 11772719     EISSN: None     Source Type: Journal    
DOI: 10.4137/BMI.S11153     Document Type: Review

References (50)

1. N.L.o. Medicine, MeSH, 2011.
2. Alberts WM, Bepler G, Hazelton T, Ruckdeschel JC, Williams JH Jr; American College of Chest Physicians. Lung cancer. Practice organization. Chest. Jan 2003;123(Suppl 1):332S-7.
3. T.N.A.o. National Working Group on Gastrointestinal Cancers. Colon cancer. Amsterdam and C.C.C. (ACCC), Colon cancer. 2008.
4. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update. CA Cancer J Clin. Mar-Apr 2010;60(2):70-98.
5. Yarnold Y. Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009. National Collaborating Centre for Cancer (UK).
6. Gold P, Freedman SO. Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques. J Exp Med. Feb 28, 1965;121(3):439-62.
7. Irgon J, Huang CC, Zhang Y, Talantov D, Bhanot G, Szalma S. Robust multitissue gene panel for cancer detection. BMC Cancer. Jun 22, 2010;10:319.
8. Pedraza V, Gomez-Capilla JA, Escaramis G, et al. Gene expression signatures in breast cancer distinguish phenotype characteristics, histologic subtypes, and tumor invasiveness. Cancer. Jan 15, 2010;116(2):486-96.
9. Tang SS, Gui GP. Biomarkers in the diagnosis of primary and recurrent breast cancer. Biomark Med. Oct 2012;6(5):567-85.
10. Yang Y, Iyer LK, Adelstein SJ, Kassis AI. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS One. 2008;3(11):e3661.
11. de Wit M, Fijneman RJ, Verheul HM, Meijer GA, Jimenez CR. Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clin Biochem. Nov 13, 2012;pii:S0009-9120(12)00623-6. doi: 10.1016/j.clinbiochem. 2012.10.039. [Epub ahead of print.]
12. Mori Y, Olaru AV, Cheng Y, et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer. Jul 4, 2011;18(4):465-78.
13. Pértega-Gomes N, Vizcaíno JR, Gouveia C, et al. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate. Nov 28, 2012. doi: 10.1002/pros.22620. [Epub ahead of print.]
14. Rizzi F, Belloni L, Crafa P, et al. A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One. 2008;3(10): e3617.
15. Rodriguez S,Al-Ghamdi OA, Burrows K, et al. Very Low PSA Concentrations and Deletions of the KLK3 Gene. Clin Chem. Nov 20, 2012.
16. Zhou X, Mao J, Ai J, et al. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PloS One. 2012;7: e48889.
17. Vansteenkiste J, Dooms C, Mascaux C, Nackaerts K. Screening and early detection of lung cancer, annals of oncology. ESMO. 2012;23(Suppl 10): 320-7.
18. Fan Y, Wang J, Yang Y, et al. Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol. Aug 2010;136(8): 1243-54.
19. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. Dec 3, 1993;75(5):843-54.
20. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. Oct 2009;10(10):704-14. doi: 10.1038/nrg2634.
21. Yu DC, Li QG, Ding XW, Ding YT. Circulating MicroRNAs: Potential Biomarkers for Cancer. Int J Mol Sci. 2011;12(3):2055-63.
22. Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. Aug 28, 2012. doi: 10.1002/ijc.27799. [Epub ahead of print.]
23. Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med. Sep 2012;30(3):680-686. doi: 10.3892/ijmm.2012.1021. Epub Jun 11, 2012.
24. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. Mar 2010;251(3):499-505.
25. Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett. Nov 2012;4(5):1027-32.
26. Raychaudhuri M, Schuster T, Buchner T, et al. Intratumoral heterogeneity of microRNA expression in breast cancer. JMD. 14, 2012:376-84.
27. Si H, Sun X, Chen Y, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. Sep 30, 2012.
28. Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. Dec 2010;119(3):586-93.
29. Hrasovec S, Glavac D. MicroRNAs as Novel Biomarkers in Colorectal Cancer. Front Genet. 2012;3:180.
30. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. Jul 1, 2010;127(1):118-26.
31. Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. Sep 2012;256(3): 544-51.
32. Menéndez P, Villarejo P, Padilla D, Menéndez JM, Montes JA. Diagnostic and prognostic significance of serum MicroRNAs in colorectal cancer. J Surg Oncol. Aug 17, 2012. doi: 10.1002/jso.23245. [Epub ahead of print.]
33. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. Oct 2009;58(10):1375-81.
34. Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. May-Jun 2012;18(3):244-52.
35. Wall N. Colorectal cancer screening using protected microRNAs. J Gastrointest Oncol. Dec 2011;2(4):206-7.
36. Wang Q, Huang S, Ni X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PloS One. 2012;7:e44398.
37. Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer. 2011;11:374.
38. Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol. Dec 2012;138(12):2045-50.
39. Alvarez-Cubero MJ, Saiz M, Martinez-Gonzalez LJ, Alvarez JC, Lorente JA, Cozar JM. Genetic analysis of the principal genes related to prostate cancer: A review. Urologic oncology. 2012.
40. Baetke SC, Adriaens ME, Seigneuric R, Evelo CT, Eijssen LM. Molecular pathways involved in prostate carcinogenesis: insights from public microarray datasets. PLoS One. 2012;7(11):e49831. doi: 10.1371/journal. pone.0049831. Epub Nov 20, 2012.
41. Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. Jun 2009;35(4): 328-34.
42. Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. Jun 2011;30(6):407-14.
43. Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q. Next-Generation Sequencing of MicroRNAs for Breast Cancer Detection. J Biomed Biotechnol. 2011;2011: 597145.
44. Sengupta N, Gill KA, MacFie TS, et al. Management of colorectal cancer: a role for genetics in prevention and treatment? Pathol Res Pract. 2008;204(7):469-77.
45. Scholefield JH. ABC of colorectal cancer: screening. BMJ. Oct 21, 2000;321(7267):1004-6.
46. Tang H, Guo Q, Zhang C, et al. Identification of an intermediate signature that marks the initial phases of the colorectal adenoma-carcinoma transition. Int J Mol Med. Nov 2010;26(5):631-41.
47. Terry MB, Neugut AI, Bostick RM, et al. Risk factors for advanced colorectal adenomas: a pooled analysis, Cancer epidemiology, biomarkers and prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002;11(7):622-9.
48. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. Mar 1, 2010; 126(5):1177-86.
49. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. Jun 26, 2008;358(26):2796-803.
50. Peng G, Hakim M, Broza YY, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. Aug 10, 2010;103(4):542-51.